| Literature DB >> 35991357 |
Peecharat Areenoo1, Chanika Manmontri1, Nattakan Chaipattanawan1, Papimon Chompu-Inwai1, Manop Khanijou2, Thongnard Kumchai2, Natthamet Wongsirichat2.
Abstract
The high success rate of dental treatment is dependent on the cooperation of pediatric patients during procedures. Dental treatment often causes pain, particularly in children. The factors in providing treatment to pediatric patients include the characteristics and location of the tooth, profoundness of the anesthesia including the type of local anesthetic, and cooperation of the patient. Previous studies have examined several techniques to successfully achieve profound pulpal anesthesia in maxillary permanent teeth. The dentist should select the injection technique to be used based on patient needs. In children, either buccal with palatal injections or buccal with intra-septal injections may be used to anesthetize the permanent maxillary first molar. Buccal with palatal injections are commonly used prior to routine maxillary dental procedures. Currently, there are only a few studies on the employment of buccal with intra-septal injections to anesthetize permanent maxillary first molars in pediatric patients. This review will focus on efficacy of buccal with palatal versus buccal with intra-septal pulpal anesthesia of the permanent maxillary first molars in pediatric patients and aim to determine which technique should be used during routine dental procedures.Entities:
Keywords: Intra-septal Injection; Maxillary Buccal Injection; Palatal Injection; Pediatric Patients; Permanent Maxillary First Molars
Year: 2022 PMID: 35991357 PMCID: PMC9358269 DOI: 10.17245/jdapm.2022.22.4.239
Source DB: PubMed Journal: J Dent Anesth Pain Med ISSN: 2383-9309
Fig. 1Buccal infiltration was performed at the lowest point of the vestibule.
Fig. 2The pressure was applied on palatal tissue to reduce pain from palatal injection.
Randomized controlled trials involving injection pain produced by palatal infiltration
| Author | Year | Sample size | Age | Teeth | Anesthetic solution | Volume | Assessment tool | Mean pain score | Pain level |
|---|---|---|---|---|---|---|---|---|---|
| Meechan, et al. [36] | 2002 | 17 | 20-24 | Max. teeth | 2% Lidocaine plain | 0.2 | 100-mm VAS | 48.18 (16.14) | moderate pain |
| 2% Lidocaine 1:80,000AD | 50.88 (15.86) | ||||||||
| Nusstein, et al. [42] | 2004 | 40 | 19-36 | Max. 1st, 2nd premolar | 2% Lidocaine1:100,000AD | N/A | 170-mm VAS | 53 (32) | mild to moderate pain |
| Fan, et al. [35] | 2009 | 71 | 17.5-67 | Max. teeth | 4% Articaine 1:100,000AD | 0.4 | 100-mm VAS | 37.70 (6.43) | mild to moderate pain |
| Kumaresan, et al. [39] | 2015 | 150 | 15-50 | Max. teeth | 2% Lidocaine 1:80,000AD | 0.3 | 11-unit NRS | 3.03 (N/A) | mild to moderate pain |
| Gazal, et al. [41] | 2017 | 90 | 16-70 | Max. teeth | 2% Mepivaine 1:100,000AD | 0.4 | 100-mm VAS | MH – 51 (17.48) | moderate pain |
| Abdellatif [1] | 2011 | 75 | 6-7 | Max. molar | 2% Lidocaine1:100,000AD | 0.3 | WBFPS | 2 = 22.6% | 2 = hurt little bit |
| 3 = 27.4% | 3 = hurt even more | ||||||||
| 4 = 40.3% | 4 = hurt whole lot | ||||||||
| 5 = 9.7% | 5 = hurt worst |
AD, adrenaline; AH, articaine hydrochloride; Max, maxillary; MH, mepivacine hydrochloride; N/A, not available; NRS, numerical rating scale; VAS, visual analog scale; WBFPS, Wong Baker facial pain rating scale.
Fig. 3Intra-septal injection was performed on the mesial aspect of the right maxillary first molar.
Studies involving injection pain produced by palatal infiltration
| Author | Year | Sample size | Age | Teeth | Anesthetic solution | Volume | Assessment tool | Mean pain score | Pain level |
|---|---|---|---|---|---|---|---|---|---|
| Saadoun & Malamed [ | 1985 | 100 | N/A | Max. teeth | 2% Lidocaine 1:50,000AD | N/A | N/A | N/A | no pain = 52% |
| Doman [ | 2011 | 113 | 7-81 | Mand. premolar, molar | 4% Articaine 1:100,000AD | 0.4 | VAS | N/A | pain-free = 62% |
| Gazal, et al. [ | 2020 | 40 | 18-70 | Mand. Molar | 2% Lidocaine1:100,000AD | 0.8 | 100-mm VAS | 16 (19.8) | mild pain |
AD, adrenaline; Mand, Mandible; Max, maxillary; N/A, not available; VAS, visual analog scale.
Studies involving anesthetic efficacy of maxillary buccal infiltration alone or with palatal infiltration for extraction or surgical removal
| Author | Year | Sample size | Age | Teeth | Treatment | Tooth condition | Anesthetic technique | Anesthetic solution | Volume (ml) | Waiting time | Evaluation method | Success rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Isik, et al. [ | 2011 | 45 | 15-76 | Max. teeth | Ext | N/A | MBI | 4% Articaine 1:100,000AD | 1.7 | 5 | NRS | 100 |
| Kanaa, et al. [ | 2012 | 100 | 16-62 | Max. premolar, 1st molar | Ext | Irreversible pulpitis | MBI | 4% Articaine 1:100,000AD | 2 | 5 | HP-VAS | 86.8 |
| 2% Lidocaine 1:80,000AD | 2 | 82.9 | ||||||||||
| Sharma, et al. [ | 2014 | 80 | 18-67 | Max. premolar, molar | Ext | N/A | MBI | 4% Articaine 1:100,000AD | 0.9 | 5 | HP-VAS | M1 – 83.33 |
| M2 – 93.33 | ||||||||||||
| M3 – 100 | ||||||||||||
| Lima-Junior, et al. [ | 2009 | 100 | 15-46 | Max. 3rd molar | Surgical removal | Impacted | MBI | (1,2) 4%AH 1:100,000AD | 1.8 | (1) 5 | Presence/absence of pain | (1) 86 |
| (2) 10 | (2) 98 | |||||||||||
| (3) 5 | (3) 78 | |||||||||||
| (4) 10 | (4) 82 | |||||||||||
| Lima, et al. [ | 2013 | 30 | 15-46 | Max. 3rd molar | Surgical removal | Partially impacted | MBI | 4% Articaine 1:100,000AD | 1.8 | 5 | 100 | |
| 4% Articaine 1:200,000AD | 1.8 | 80 | ||||||||||
| Uckan, et al. [ | 2006 | 53 | 18-48 | Max. teeth | Ext | N/A | MBI | 4% Articaine 1:100,000AD | 2 | 5 | VAS, FPS | 96.8 |
| MBI + PI | 1.75 + 0.25 | 97.5 | ||||||||||
| Peng, et al. [ | 2008 | 104 | 18-56 | Max. teeth | Ext | N/A | MBI | 4% Articaine 1:100,000AD | 1.7 | 5 | VAS | 96.15 |
| MBI + PI | 4% AH+2% LH1:100,000AD | 1.7 + 0.25 | 97.12 | |||||||||
| Hong, et al. [ | 2008 | 28 | 18-43 | Max. 3rd molar | Ext | N/A | MBI | 4% Articaine 1:100,000AD | 1.5 | 5 | VAS | 82.14 |
| MBI + PI | 1.7 + 0.4 | 92.86 | ||||||||||
| Fan, et al. [ | 2009 | 71 | 17.5-67 | Max. teeth | Ext | N/A | MBI | 4% Articaine 1:100,000AD | 1.7 | 5 | VAS, VRS | 95.77 |
| MBI + PI | 1.7 + 0.4 | 97.18 | ||||||||||
| Somuri, et al. [ | 2013 | 30 | 10-30 | Max. premolar | Ext | Orthodontic teeth | MBI | 4% Articaine 1:100,000AD | 1.7 | N/A | FPS, VAS | 90 |
| MBI + PI | 2% Lidocaine1:100,000AD | 1.75 + 0.25 | 100 | |||||||||
| Luqman, et al. [ | 2015 | 194 | 20-60 | Max. teeth | Ext | N/A | MBI | 4% Articaine 1:200,000AD | 1.7 | * | FPS, VAS | 84 |
| MBI + PI | 2% Lidocaine1:100,000AD | 1 + 0.2-0.4 | 100 |
AD, adrenaline; AH, articaine hydrochloride; Ext, extraction; FPS, faces pain scale; HP-VAS, Heft-Parker visual analog scale; LH, lidocaine hydrochloride; M1, first molar; M2, second molar; M3, third molar; Max, maxillary; MBI, maxillary buccal infiltration; N/A, not available; NRS, numerical rating scale; PI, palatal infiltration; VAS, visual analog scale; VRS, verbal rating scale.
*Depending on time to anesthesia on probing of palatal mucosa
Randomized controlled trials involving pulpal anesthetic efficacy of maxillary buccal infiltration alone or with palatal infiltration for endodontic treatment
| Author | Year | Sample size | Age | Teeth | Treatment | Tooth condition | Anesthetic technique | Anesthetic solution | Volume | Waiting time | Evaluation method | Success rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross, et al. [ | 2007 | 65 | 18-26 (24) | Max. incisor, 1st molar | None | Healthy teeth | MBI | 0.5% Bupivacaine 1:200,000AD | 1.8 | 3min/cont.in 3-min cycles for 120 min | EPT | 64 |
| 2% Lidocaine 1:100,000AD | 82 | |||||||||||
| Mikesell, et al. [ | 2008 | 96 | 21-43 | Max. teeth | None | Healthy teeth | MBI | 2% Lidocaine 1:100,000AD | 1.8 | 3min/cont.in 3-min cycles for 60 min | EPT | 100 |
| 3.6 | 97 | |||||||||||
| Evans,
et al. [ | 2008 | 40 | 20-33 (24) | Max. 1st molar | None | Healthy teeth | MBI | 4% Articaine 1:100,000AD | 1cart | 1min/cont.in 3-min cycles for 60 min | EPT/VAS | 78 |
| 2% Lidocaine 1:100,000AD | 72.5 | |||||||||||
| Mason,
et al. [ | 2009 | 30 | 19-43 | Max. incisor, 1st molar | None | Healthy teeth | MBI | 2% Lidocaine 1:100,000AD | 1.8 | 1min/cont.in 3-min cycles for 60 min | EPT | 97 |
| 2% Lidocaine 1:50,000AD | 93 | |||||||||||
| 3% Mepivacaine | 93 | |||||||||||
| Katz,
et al. [ | 2010 | 60 | 22-31 | Max. incisor, 1st molar | None | Healthy teeth | MBI | 2% Lidocaine 1:100,000AD | 1.8 | 1min/cont.in 3-min cycles for 60 min | EPT | 83 |
| 4% Prilocaine 1:100,000AD | 80 | |||||||||||
| 4% Prilocaine 1:200,000AD | 93 | |||||||||||
| Guglielmo, et al. [ | 2011 | 40 | 22-32 | Max. 1st molar | None | Healthy teeth | MBI | 2% Lidocaine 1:100,000AD | 1.8 + mock | 5min/cont.in 4-min cycles for 60 min | EPT | 88 |
| MBI + PI | 1.8 + 0.5 | 95 | ||||||||||
| Srinivasan, et al. [ | 2009 | 40 | 18-40 | Max. premolar, 1st molar | Access cavity | Irreversible pulpitis | MBI | 4% Articaine 1:100,000AD | 1.7 | 5 | VAS | 100, 100 |
| 2% Lidocaine1:100,000AD | 1.7 | 80,30 (premolar, molar) | ||||||||||
| Hosseini, et al. [ | 2016 | 50 | >18 | Max. molar | Access cavity | Access cavity | MBI | 4% Articaine 1:100,000AD | 1.8 | 5 | HP-VAS | 66.67 |
| 2% Lidocaine 1:80,000AD | 56.52 | |||||||||||
| Aggarwal, et al. [ | 2011 | 94 | 21-39 | Max. 1st molar | Access cavity | Access cavity | MBI | 2% Lidocaine 1:200,000AD | 1.8 | 15 | HP-VAS | 54 |
| MBI + PI | 1.8 + 0.5 | 70 |
AD, adrenaline; EPT, electric pulp testing; HP-VAS, Heft-Parker visual analog scale; Max, maxillary; MBI, maxillary buccal infiltration; N/A, not available; PI, palatal infiltration; VAS, visual analog scale.
Studies involving anesthetic efficacy of intraseptal injection for extraction or other treatments
| Author | Year | Sample size | Age | Teeth | Treatment | Tooth condition | Anesthetic technique | Anesthetic solution | Volume | Waiting time | Evaluation method | Success rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brkovic, et al. [ | 2010 | 35 | (37 ± 12.3) | Max. lateral incisor | Ext | unrestorable or failure ornon-vitalteeth | IS or PLA as primary injection | 2% Lidocaine 1:100,000AD | 0.2 × 4 (MB, DB, MP, DP) | 20 sec | VAS | IS – 88.6 |
| PLA–91.4 | ||||||||||||
| Doman, [ | 2011 | 113 | 7-81 | Mand. premolar, molar | Restorative treatment | N/A | IANB + IS | 4% Articaine 1:100,000AD | N/A + 0.4 | N/A | VAS | 87 |
| Gazal, et al. [ | 2020 | 200 | 18-65 | Mand. Molar | Ext or endodontic treatment | N/A | 2% Lidocaine 1:100,000AD | 1.8 + 0.9 | 10 min | HP-VAS | 37.5 | |
| 2% LH1:105AD for IS or 4% AH1:105AD for BI | IS–0.8 | 20sec 10min | 75 | |||||||||
| BI–N/A | 62.5 |
AD, adrenaline; AH, articaine hydrochloride; BI, buccal infiltration; BNB, long buccal nerve block; DB, distobuccal; DP, distopalatal; Ext, extraction; HP-VAS, Heft-Parker visual analog scale; IANB, inferior alveolar nerve block; IS, intraseptal injection; LH, lidocaine hydrochloride; Max, maxillary; Mand, mandibular; MB, mesiobuccal; MP, mesiopalatal; N/A, not available; PLA, periodontal ligament anesthesia; VAS, visual analog scale.
Studies involving pulpal anesthetic efficacy of intra-septal injection for endodontic treatment
| Author | Year | Sample size | Age | Teeth | Treatment | Tooth condition | Anesthetic technique | Anesthetic solution | Volume | Waiting time | Evaluation method | Success rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocanin, et al. [ | 2013 | 180 | 24-31 | Mand. first premolar | None | Healthy teeth | IS with CCLAD | 4% Articaine 1:100,000AD | 0.4 | 2-min interval | EPT | 73 |
| 0.6 | 90 | |||||||||||
| 0.8 | 90 | |||||||||||
| Pandrangi [ | 2015 | 100 | 19-43 | Mand. premolar, molar | None | Healthy teeth | IS with CCLAD as primary injection | 4% Articaine 1:100,000AD | 0.7 + 0.7 | 1min/cont. in 2-min cycles for 60 min | EPT/HP-VAS | AH: |
| 2% Lidocaine 1:100,000AD | ||||||||||||
| Bonar, et al. [ | 2017 | 100 | 19-43 | Mand. 1st molar | None | Healthy teeth | IS with CCLAD as primary injection | 4% Articaine 1:100,000AD | 0.7 + 0.7 | 1min/cont. in 4-min cycles for 60 min | HP-VAS | 32 |
| 2% Lidocaine1:100,000AD | 30 | |||||||||||
| Webster, et al. [ | 2016 | 100 | 18-65 | Mand. posterior teeth | Endodontic access | Symptomatic irreversible pulpitis | IANB + BNB + IS with CCLAD as supplemental injection | 2% Lidocaine 1:100,000AD + 4% Articaine 1:100,000AD | 1.8 + 0.9 | 15 min | HP-VAS/VAS | IANB-25 |
| IS-29 | ||||||||||||
| Dianat, et al. [ | 2019 | 90 | 18-65 | Mand. Molar | Endodontic access | Symptomatic irreversible pulpitis | (1) IANB | (1) 2% LH 1:100,000AD | (1) 1.7 | 10 min | VAS, EPT | (1) 30.33 |
| (2) IANB+BI | (2) 2% LH + 4%AH 1:105AD | (2) 1.7 + 1.7 | (2) 66.66 | |||||||||
| (3) IANB+BI, IS | (3) 2% LH + 4%AH 1:105AD | (3) 1.7 + 1.7 + (0.85 x 2) | (3) 80.88 | |||||||||
| Gazal, et al. [ | 2020 | 200 | 18-65 | Mand. Molar | Ext or endodontic treatment | N/A | IANB + BNB supplement with IS or BI | 2% Lidocaine 1:100,000AD | 1.8 + 0.9 | 10 min | HP-VAS | 37.5 |
| 2% LH1:105AD for IS IS–0.8 or 4% AH1:105AD for BI | IS–0.8 | 20 sec 10 min | 75 | |||||||||
| BI–N/A | 62.5 |
AD, adrenaline; AH, articaine hydrochloride; BI, buccal infiltration; BNB, long buccal nerve block; CCLAD, computer-controlled local anesthesia delivery; D, distal; EPT, electric pulp testing; Ext, extraction; HP-VAS, Heft-Parker visual analog scale; I2, lateral incisor; IANB, inferior alveolar nerve block; IS, intraseptal injection; LH, lidocaine hydrochloride; M, mesial; M1, first molar; M2, second molar; Mand, mandibular; N/A, not available; P2, second premolar; VAS, visual analog scale.